Differential processing of antitumour-active and antitumour-inactive trans platinum compounds by SKOV-3 ovarian cancer cells

Biochem Pharmacol. 2006 Jul 28;72(3):280-92. doi: 10.1016/j.bcp.2006.04.021. Epub 2006 May 1.

Abstract

In order to compare the mechanistic properties of the antitumour-active trans platinum complex trans-[PtCl(2){Z-HN=C(OMe)Me}(NH(3))] (trans-Z) and of the antitumour-inactive isomer of cisplatin trans-[PtCl(2)(NH(3))(2)] (trans-DDP), the differential processing of the two compounds by SKOV-3 ovarian cancer cells has been investigated. trans-Z and trans-DDP enter cells with the same efficacy, but trans-Z shows a two-fold higher affinity for cellular DNA. The treatment with trans-DDP IC(50) determines an initial and transient cytostatic effect, paralleled by a moderate increase of apoptosis and by sequential and reversible arrests in S and G(2)/M phases of cell-cycle. In contrast, trans-Z IC(50) determines an initial cytotoxic effect, a more persistent and marked increase of apoptosis, and a more marked and prolonged arrest in S and G(2)/M phases of the cell-cycle. Treatment-induced gene expression modifications indicate that phenotypic effects of trans-DDP are driven by an initial and transient up-regulation of some genes related to cell-cycle checkpoint and arrest networks, whereas the more dramatic phenotypic effects of trans-Z are driven by a persistent up-regulation of more numerous genes involved in cell-cycle checkpoint and arrest networks, and in genome stability and DNA repair. Therefore, molecular and cellular events have been identified which are produced by trans-Z but not by trans-DDP, and which likely represent the mechanistic basis of antitumour activity of trans-Z in the SKOV-3 system.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / toxicity*
  • Apoptosis / genetics
  • Cell Cycle / drug effects
  • Cell Cycle Proteins / genetics
  • Cell Line, Tumor
  • Cell Proliferation / drug effects*
  • Cell Survival / drug effects
  • Cisplatin / chemistry
  • Cisplatin / metabolism
  • Cisplatin / toxicity*
  • Cross-Linking Reagents / chemistry
  • Cross-Linking Reagents / toxicity
  • DNA Fragmentation / drug effects
  • DNA Repair / genetics
  • Female
  • Flow Cytometry
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic / drug effects
  • Genomic Instability / genetics
  • Inhibitory Concentration 50
  • Organoplatinum Compounds / chemistry
  • Organoplatinum Compounds / metabolism
  • Organoplatinum Compounds / toxicity*
  • Ovarian Neoplasms / genetics
  • Ovarian Neoplasms / metabolism
  • Ovarian Neoplasms / pathology
  • Stereoisomerism

Substances

  • Antineoplastic Agents
  • Cell Cycle Proteins
  • Cross-Linking Reagents
  • Organoplatinum Compounds
  • dichlorobis(1-methoxyethanimine)platinum(II)
  • transplatin
  • Cisplatin